CoChat
Sign Up
Cited by 418Gastrointestinal motility and disordersNausea and vomiting managementHealth Education and Validation

The DOI matches its Crossref record; the references it cites are not checked yet.

Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms

Revicki, Dennis A., Rentz, Anne M., Dubois, Dominique, Kahrilas, Peter, Stanghellini, Vincenzo, Talley, Nicholas J., Tack, Jan·2004·Quality of Life Research
DOI 10.1023/b:qure.0000021689.86296.e4
Open this paper in CoChat — free account

Abstract

Background Patient-rated symptom assessments are needed for evaluating the effectiveness of medical treatments and for monitoring outcomes in gastroparesis. Objective This paper summarizes the development and psychometric evaluation of a new instrument, the Gastroparesis Cardinal Symptom Index (GCSI), for assessing severity of symptoms associated with gastroparesis. Methods The GCSI was based on reviews of the medical literature, patient focus groups, and interviews with clinicians. A sample of 169 patients with a documented diagnosis of gastroparesis participated in the psychometric evaluation study. Patients completed the GCSI, the SF-36 Health Survey, and disability days questions at baseline and after 8 weeks. A randomly selected sub-sample of 30 subjects returned at 2 weeks to assess test retest reliability. Clinicians rated severity of symptoms, and both clinicians and patients rated change in gastroparesis-related symptoms over the 8 week study. Results The GCSI is based on three subscales: post-prandial fullness/early satiety (4 items); nausea/vomiting (3 items), and bloating (2 items). Internal consistency reliability was 0.84 for the GCSI total score and ranged from 0.83 to 0.85 for the subscale scores. Two week test retest reliability was 0.76 for the total score and ranged from 0.68 to 0.81 for subscale scores. Construct validity was supported, given that we observed significant relationships between clinician assessed symptom severity and GCSI total score, signif…

Overview

Integrity signals

Registry

Crossref · 10.1023/b:qure.0000021689.86296.e4

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The Gastroparesis Cardinal Symptom Index (GCSI) and the Patient Assessment of Gastrointestinal Disorders-Symptom Severity Index (PAGI‐SYM) provide validated, quantitative measures of gastroparetic symptoms and are useful for screening and monitoring treatment response in clinical practice and trials.

    “The Gastroparesis Cardinal Symptom Index (GCSI) and the Patient Assessment of Gastrointestinal Disorders–Symptom Severity Index (PAGI‑SYM) provide validated, quantitative measures of gastroparetic symptoms and are useful for screening and monitoring treatment response in clinical practice and trials [62, 63].”

    From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [62]

Citations

The citation lists haven’t been fetched yet

References 38 · Cited by 418

Research works printed but not linked: 36

  1. Horowitz M, Fraser RJL. Gastroparesis: Diagnosis and management. Scand J Gastroenterol 1995; 30(Suppl 213): 7-16.
  2. Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America. Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000; 45: 809-818. · DOI
  3. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997; 92: 976-980.
  4. Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: An overview. Diabetes Med 1996; 13(9 Suppl 5): S16-S22.
  5. Leidy NK, Farup C, Rentz AM, Ganoczy D, Koch KL. Patient-based assessment in dyspepsia: Development and validation of Dyspepsia Symptom Severity Index (DSSI). Dig Dis Sci 2000; 45: 1172-1179. · DOI
  6. Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 315-324. · DOI
  7. Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP. SODA (severity of dyspepsia assessment): A new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 2001; 54: 755-765. · DOI
  8. Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality of life measures for use in selected gastrointestinal disease studies: A review and synthesis of the literature. Pharmacoeconomics 2001; 19: 349-363. · DOI
  9. Revicki DA, Sorensen S, Maton PN, Orlando RC. Healthrelated quality of life outcomes of omeprazole versus. ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 284-291. · DOI
  10. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJC. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985: 30: 1-9. · DOI
  11. Jones KL, Wishart JM, Berry MK, et al. Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis. Aliment Pharmacol Ther 2000; 14: 937-943. · DOI
  12. Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: Efficacy, tolerability, and quality of life outcomes in a multicenter controlled trial. Clin Ther 1998; 20: 438-453. · DOI
  13. Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998; 21: 1699-1706. · DOI
  14. Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: Effect of long-term domperidone therapy. Am J Gastroenterol 1989; 84: 1069-1075.
  15. Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 1230-1234.
  16. Talley NJ, Verlinden M, Greenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: A randomized, double blind, placebo controlled trial. Gut 2001; 49: 395-401. · DOI
  17. Rentz AM, Schmier J, De La Loge C, et al. Development and preliminary psychometric validation of the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) in GI patients. Presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Antwerp, Belgium, November 2000. · DOI
  18. Schmier J, Rentz AM, De La Loge C, et al. Development and preliminary psychometric validation of the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) in gastroparesis. Presented at the annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Antwerp, Belgium, November 2000. · DOI
  19. Acquadro C, Jambon B, Ellis D, Marquis P. Language and translation issues. In: Spilker B (ed.). Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd ed. Philadelphia: Lippincott-Raven, 1996; 575-586.
  20. Bullinger M, Anderson R, Cella D, Aaronson N. Developing and evaluating cross-cultural instruments from minimum requirements to optimal models. Qual Life Res 1993; 2: 451-459. · DOI
  21. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, Massachusetts: The Health Institute, New England Medical Center, 1993.
  22. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clinic Proceed 2002; 77: 371-383. · DOI
  23. Jaeschke R, Singer J, Guyatt GH. Measurements of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 407-415. · DOI · Paper page
  24. Juniper EF, Guyatt GH, Willian A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 81-87. · DOI · Paper page
  25. Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, Massachusetts: The Health Institute, New England Medical Center, 1994.
  26. Bityutskiy JP, Soykan I, McCallum RW. Viral gastroparesis: A subgroup of idiopathic gastroparesis — clinical characteristics and long-term outcomes. Am J Gastroenterol 1997; 92(9): 1501-1504.
  27. Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA 1990; 264: 2524-2528. · DOI
  28. Revicki DA, Irwin D, Reblando J, Simon GE. The accuracy of self-reported disability days. Med Care 1994; 32: 401-404. · DOI
  29. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intraindividual changes in health-related quality of life. Med Care 1999a; 37: 469-478. · DOI
  30. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999b; 52: 861-873. · DOI
  31. Hays RD, Anderson RT, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: Staquet MJ, Hays RD, Fayers PM (eds), Quality of Life Assessment in Clinical Trials: Methods and Practice, Oxford: Oxford University Press, 1998.
  32. Nunnally JC, Bernstein IH. Psychometric Theory, 3rd ed. New York: McGraw-Hill, 1994.
  33. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Erlbaum, 1988.
  34. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. For the European Regulatory Issues on Quality of Life Assessment Group. Patient-reported outcomes: The example of health-related quality of life — a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inform J 2002; 36: 209-218. · DOI
  35. Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 113-127. · DOI
  36. Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887-900. · DOI

Metadata

Authors
Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J.
Affiliations
  • Johnson & Johnson (United States) (US)
  • Northwestern University (US)
  • University of Bologna (IT)
  • The University of Sydney (AU)
  • KU Leuven (BE)
Corresponding author
Revicki, Dennis A.
ORCID
Venue
Quality of Life Research
Publisher
Springer Science and Business Media LLC
Published
2004-05
Volume
13
Issue
4
Pages
833-844
ISSN
  • 0962-9343 (ISSN-L)
  • 1573-2649
DOI
10.1023/b:qure.0000021689.86296.e4
OpenAlex
W2054782808
Cited by
418
References
38
Citations by year
2026: 23 · 2025: 34 · 2024: 34 · 2023: 27 · 2022: 41 · 2021: 31 · 2020: 28 · 2019: 36 · 2018: 22 · 2017: 23 · 2016: 9 · 2015: 17 · 2014: 9 · 2013: 18 · 2012: 16
FWCI
2.36
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Quality of Life Research (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Health Sciences › Nursing › Research and Theory › Health Education and Validation
Keywords
gastroparesis, Gastroparesis Cardinal Symptom Index, patient-reported outcome measures, symptom severity assessment, postprandial fullness, early satiety, nausea and vomiting, bloating, psychometric validation, test-retest reliability, construct validity, responsiveness to change, disability days
MeSH terms
Adolescent, Adult, Aged, Disability Evaluation, Dyspepsia, Europe, Female, Humans, Male, Middle Aged, Psychometrics, Surveys and Questionnaires, Sampling Studies, Self-Assessment, Severity of Illness Index, United States, Treatment Outcome, Sickness Impact Profile, Gastroparesis, Internationality

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review